undamentalytics Newsletter
Sign in

Alnylam Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Alnylam Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $10,363 2 trades by 1 insider 3 months later: median −13.8% (−18.6% vs S&P 500) Insider sales, 5 years $213M 127 trades by 15 insiders 3 months later: median −3.2% (−7.5% vs S&P 500)
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Alnylam Pharmaceuticals, Inc.’s insiders pay?

From April 26, 2010 to October 6, 2026, 23 insiders reported 20 open-market purchases and 65 sales not made under a pre-set plan in Alnylam Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were +23.5% against the S&P 500 on average (median +3.3%), over 20 purchases with a full year of prices; 50% beat the index. After sales, the shares moved +5.9% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 27, 2010 into $125,369 by November 2, 2026, +16.6% a year. It held shares 45% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $35,660 (+8.0% a year), and held throughout $85,415 (+13.9%).

$0$50.0k$100k 201020122014201620182020202220242026 $125k$85.4k$35.7k
Copying Alnylam Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Alnylam Pharmaceuticals, Inc.'s insiders from April 27, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 45% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Greenstreet Yvonne Chief Executive Officer 0 — — 15 +5.5% (11) March 6, 2026
Poulton Jeffrey V. EVP, Chief Financial Officer 0 — — 15 +5.5% (11) March 6, 2026
Tanguler Tolga EVP, Chief Commercial Officer 0 — — 13 +1.5% (9) March 6, 2026
Garg Pushkal EVP Chief R&D 0 — — 7 +37.6% (5) February 17, 2026
Sanofi 10% owner 5 −3.6% (5) 40% 0 — June 1, 2017
Fitzgerald Kevin Joseph CSO & EVP, Head of Research 0 — — 4 −27.2% (4) October 3, 2025
Bonney Michael W Director 2 −45.9% (2) 0% 1 +24.5% (1) August 4, 2023
Franchini Indrani Lall EVP, CLO & Secretary 0 — — 3 +12.4% (3) February 29, 2024
Vincent James L Director 0 — — 3 −56.8% (3) June 18, 2010
Maraganore John Chief Executive Officer 2 +18.9% (2) 50% 0 — January 28, 2015
Sharp Phillip A Director 2 +134.1% (2) 100% 0 — January 24, 2013
Vaishnaw Akshay President 0 — — 2 −10.7% (2) August 7, 2023
Fanucci Marsha Director 1 +61.9% (1) 100% 0 — February 23, 2012
Greene Barry E President and COO 1 +61.9% (1) 100% 0 — February 23, 2012
Gros David-Alexandre C SVP, Chief Business Officer 1 −41.7% (1) 0% 0 — February 24, 2016
Keating Laurie SVP, GC and Secretary 1 +29.8% (1) 100% 0 — May 31, 2017
Novartis AG 10% owner 1 −59.2% (1) 0% 0 — April 26, 2010
Novartis Pharma AG 10% owner 0 — — 1 +210.8% (1) September 24, 2012
Paul Steven M Director 1 −24.1% (1) 0% 0 — January 28, 2015
Pyott David E I Director 1 +201.8% (1) 100% 0 — October 14, 2016
Reitan Colleen F Director 1 −19.0% (1) 0% 0 — May 12, 2025
Schimmel Paul Director 1 +61.9% (1) 100% 0 — February 23, 2012
Supran Bryan EVP, CLO and Secretary 0 — — 1 — October 6, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Alnylam Pharmaceuticals, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Alnylam Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged +29.2% against the index. After 7 selling crowds, +6.2%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
August 29, 20254 selling−5.2%−34.7%−64.3%
March 31, 20255 selling+8.5%+49.1%+3.3%
November 29, 20244 selling+1.4%+21.1%+72.1%
June 28, 20245 selling+7.8%−12.1%+20.3%
February 29, 20245 selling−3.9%+79.4%+45.8%
August 31, 20234 selling−16.6%−38.8%+4.0%
May 31, 20234 selling−1.8%−20.9%−47.8%
June 30, 20172 buying+42.9%+47.8%+8.4%
February 29, 20162 buying+6.2%+7.5%−36.6%
January 30, 20153 buying+7.8%+29.3%−24.8%
February 29, 20125 buying−21.3%+32.1%+66.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Alnylam Pharmaceuticals, Inc. · Funds · Politicians